Sciegen Pharmaceuticals Inc FDA Record
- Latest inspection VAI · May 15, 2026
- No warning letters matched by name
Sciegen Pharmaceuticals Inc has 7 FDA recalls, 14 inspections, 0 510(k) clearances and 0 compliance actions on record. No FDA warning letter addressed to "Sciegen Pharmaceuticals Inc" is on file.
- Latest recall
- D-0354-2023 · Class III · Feb 17, 2023
- Latest inspection
- May 15, 2026 · VAI
Summary
| Records | Count | Last refreshed | Source as of | Status |
|---|---|---|---|---|
| Recalls | 7 | Nov 11, 2026 (checked Nov 15, 2026, unchanged) | File dated Nov 10, 2026 | Current |
| 510(k) clearances | 0 | Nov 15, 2026 | File dated Nov 9, 2026 | Current |
| Inspections | 14 | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions | 0 | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
FDA record by year
Sciegen Pharmaceuticals Inc: FDA inspections per year
| Year | Inspections | OAI | Warning letters | Recall records | Class I |
|---|---|---|---|---|---|
| 2026 | 1 | 0 | 0 | 0 | 0 |
| 2025 | 1 | 0 | 0 | 0 | 0 |
| 2024 | 1 | 0 | 0 | 0 | 0 |
| 2023 | 1 | 1 | 0 | 1 | 0 |
| 2022 | 1 | 0 | 0 | 0 | 0 |
| 2021 | 1 | 0 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 0 | 0 | 0 |
| 2019 | 1 | 0 | 0 | 0 | 0 |
| 2018 | 3 | 0 | 0 | 6 | 0 |
| 2017 | 0 | 0 | 0 | 0 | 0 |
Reviewing Sciegen Pharmaceuticals Inc as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Sciegen Pharmaceuticals Inc yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Recent recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0354-2023 | Class III | Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen… | Feb 17, 2023 |
| D-0271-2019 | Class II | GSMS Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 60429-641-30), (b) 90-count bottle… | Oct 29, 2018 |
| D-0268-2019 | Class II | Westminister Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 69367-120-01), (b) 90-count… | Oct 29, 2018 |
| D-0267-2019 | Class II | Westminister Irbesartan Tablets, USP, 75 mg (a) 30-count bottle (NDC 69367-119-01), (b) 90-count… | Oct 29, 2018 |
| D-0270-2019 | Class II | GSMS Irbesartan Tablets, USP, 75 mg, 30-count bottle, Rx Only, Manufactured by ScieGen… | Oct 29, 2018 |
| D-0272-2019 | Class II | GSMS Irbesartan Tablets, USP, 300 mg,(a) 30-count bottle (NDC 60429-642-30), (b) 90-count bottle… | Oct 29, 2018 |
| D-0269-2019 | Class II | Westminister Irbesartan Tablets, USP, 300mg, Rx Only,(a) 30-count bottle (NDC 69367-121-01, (b)… | Oct 29, 2018 |
Recent FDA inspections
| Date | Site | Product | Classification | FEI |
|---|---|---|---|---|
| May 15, 2026 | Hauppauge, NY | Drugs | Voluntary Action Indicated (VAI) | 3008298016 |
| Dec 19, 2025 | Hauppauge, NY | Drugs | No Action Indicated (NAI) | 3008298016 |
| Feb 20, 2024 | Hauppauge, NY | Drugs | No Action Indicated (NAI) | 3008298016 |
| Apr 21, 2023 | Hauppauge, NY | Drugs | Official Action Indicated (OAI) | 3008298016 |
| Sep 2, 2022 | Hauppauge, NY | Drugs | Voluntary Action Indicated (VAI) | 3008298016 |
| Dec 20, 2021 | Hauppauge, NY | Drugs | Voluntary Action Indicated (VAI) | 3008298016 |
| Jun 21, 2019 | Hauppauge, NY | Drugs | Voluntary Action Indicated (VAI) | 3008298016 |
| Apr 20, 2018 | Hauppauge, NY | Drugs | No Action Indicated (NAI) | 3008298016 |
| Mar 16, 2018 | Hauppauge, NY | Drugs | No Action Indicated (NAI) | 3008298016 |
| Mar 14, 2018 | Hauppauge, NY | Drugs | No Action Indicated (NAI) | 3008298016 |
| Jan 9, 2015 | Hauppauge, NY | Drugs | Voluntary Action Indicated (VAI) | 3008298016 |
| Sep 18, 2013 | Hauppauge, NY | Drugs | No Action Indicated (NAI) | 3008298016 |
| Apr 2, 2013 | Hauppauge, NY | Drugs | No Action Indicated (NAI) | 3008298016 |
| Sep 16, 2011 | Hauppauge, NY | Drugs | Voluntary Action Indicated (VAI) | 3008298016 |
- NAI
- No objectionable conditions or practices were found during the inspection.
- VAI
- Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
- OAI
- Regulatory and/or administrative actions are recommended.
FDA-inspected facilities
| Facility | Location | Inspections | Latest |
|---|---|---|---|
| FEI 3008298016 | Hauppauge, NY | 14 | May 15, 2026 |
Sciegen Pharmaceuticals Inc and the FDA: common questions
Has Sciegen Pharmaceuticals Inc received an FDA warning letter?
No FDA warning letter addressed to the name "Sciegen Pharmaceuticals Inc" is on file. This answer covers that name only: letters addressed to a related company name or to one of its sites are listed on that name's or site's own page.
Has Sciegen Pharmaceuticals Inc received an FDA Form 483?
FDA has not published a Form 483 for "Sciegen Pharmaceuticals Inc" in its reading room. FDA publishes some Form 483s, not all of them.
When did the FDA last inspect Sciegen Pharmaceuticals Inc?
The most recent FDA inspection on file ended May 15, 2026 at Hauppauge, NY and was classified VAI. FDA has 14 inspections of Sciegen Pharmaceuticals Inc on file, 1 of them classified OAI (official action indicated).
Has Sciegen Pharmaceuticals Inc had an FDA recall?
Yes. Sciegen Pharmaceuticals Inc has 7 FDA recalls on record. The most recent started Feb 17, 2023.
Need more than this page shows? Ask about Sciegen Pharmaceuticals Inc in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.